These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 19897050

  • 1. Epigenetic opportunities and challenges in cancer.
    Best JD, Carey N.
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Epigenetic alterations and cancer: new targets for therapy.
    Allen A.
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [Abstract] [Full Text] [Related]

  • 4. Epigenetic gene regulation in cancer.
    Ballestar E, Esteller M.
    Adv Genet; 2008 Oct; 61():247-67. PubMed ID: 18282509
    [Abstract] [Full Text] [Related]

  • 5. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM.
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Novel approaches on epigenetics.
    Papait R, Monti E, Bonapace IM.
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
    [Abstract] [Full Text] [Related]

  • 9. Unraveling the epigenetic code of cancer for therapy.
    Smith LT, Otterson GA, Plass C.
    Trends Genet; 2007 Sep; 23(9):449-56. PubMed ID: 17681396
    [Abstract] [Full Text] [Related]

  • 10. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
    Baker EK, Johnstone RW, Zalcberg JR, El-Osta A.
    Oncogene; 2005 Dec 01; 24(54):8061-75. PubMed ID: 16091741
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The clinical application of targeting cancer through histone acetylation and hypomethylation.
    Gilbert J, Gore SD, Herman JG, Carducci MA.
    Clin Cancer Res; 2004 Jul 15; 10(14):4589-96. PubMed ID: 15269129
    [Abstract] [Full Text] [Related]

  • 16. Chromatin modifying agents - the cutting edge of anticancer therapy.
    Kwa FA, Balcerczyk A, Licciardi P, El-Osta A, Karagiannis TC.
    Drug Discov Today; 2011 Jul 15; 16(13-14):543-7. PubMed ID: 21664485
    [Abstract] [Full Text] [Related]

  • 17. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM, Strathdee G, Brown R.
    Drug Resist Updat; 2004 Jul 15; 7(4-5):267-78. PubMed ID: 15533764
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S, Fields CR, Su N, Pan YX, Robertson KD.
    Oncogene; 2007 Apr 19; 26(18):2621-34. PubMed ID: 17043644
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Epigenetics and cancer treatment.
    Kristensen LS, Nielsen HM, Hansen LL.
    Eur J Pharmacol; 2009 Dec 25; 625(1-3):131-42. PubMed ID: 19836388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.